Compare AbCellera Biologics Inc (ABCL) vs Dollar General Corp. (DG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Dollar General Corp. — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Dollar General Corp. trades at $115.92 (market cap $25.46B). The key difference: Dollar General Corp. is far larger — about 10.8× AbCellera Biologics Inc's market cap, and Dollar General Corp. pays a 2.04% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DG | |
|---|---|---|
Market Cap | $2.35B | $25.46B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $156.26 |
52-Week Low | $2.78 | $95.94 |
Enterprise Value | $1.99B | $39.91B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Dollar General (DG) trades at $115.43, down 2.32% on the day, with technical indicators showing a neutral to bearish short-term bias. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.00 surpassing the $1.89 estimate. Fundamentals reveal steady revenue growth to $40.61 billion in 2025, though net income margin has compressed to 2.77%. Positive cash flow trends and a manageable debt-to-asset ratio of 20.03% support financial health.
The investment outlook is cautiously optimistic, driven by analyst consensus favoring a Buy rating with a $128.91 price target, implying ~12% upside. Key opportunities include margin expansion initiatives and the DG Media Network, while risks involve consumer spending sensitivity and competitive pressures. The current valuation at a P/E of 16.45 appears reasonable relative to historical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
